Background-Human cardiac progenitor cells (hCPCs) are a promising cell source for regenerative repair after myocardial infarction. Exploitation of their full therapeutic potential may require stable genetic modification of the cells ex vivo. Safe genetic engineering of stem cells, using facile methods for site-specific integration of transgenes into known genomic contexts, would significantly enhance the overall safety and efficacy of cellular therapy in a variety of clinical contexts. Methods and Results-We used the phiC31 site-specific recombinase to achieve targeted integration of a triple fusion reporter gene into a known chromosomal context in hCPCs and human endothelial cells. Stable expression of the reporter gene from its unique chromosomal integration site resulted in no discernible genomic instability or adverse changes in cell phenotype. Namely, phiC31-modified hCPCs were unchanged in their differentiation propensity, cellular proliferative rate, and global gene expression profile when compared with unaltered control hCPCs. Expression of the triple fusion reporter gene enabled multimodal assessment of cell fate in vitro and in vivo using fluorescence microscopy, bioluminescence imaging, and positron emission tomography. Intramyocardial transplantation of genetically modified hCPCs resulted in significant improvement in myocardial function 2 weeks after cell delivery, as assessed by echocardiography (Pϭ0.002) and MRI (Pϭ0.001). We also demonstrated the feasibility and therapeutic efficacy of genetically modifying differentiated human endothelial cells, which enhanced hind limb perfusion (PϽ0.05 at day 7 and 14 after transplantation) on laser Doppler imaging. Conclusions-The phiC31 integrase genomic modification system is a safe, efficient tool to enable site-specific integration of reporter transgenes in progenitor and differentiated cell types. (Circulation. 2012;126[suppl 1]:S20 -S28.)
C ardiovascular disease remains one of the leading causes of morbidity and mortality in the United States and globally. After a myocardial infarction, the limited proliferative ability of the surviving myocardial cells renders the heart susceptible to morbid sequelae such as unfavorable remodeling and ischemic cardiomyopathy. Recently, stem cell therapy has emerged as a promising adjunct to existing pharmacological and device treatment options. 1, 2 In particular, human cardiac progenitor cells (hCPCs) are attractive candidates for clinical translation of cell therapy. 3 hCPCs can be autologously derived, obviating the need for immune suppression after transplantation, and are preprogrammed for differentiation into the three principal cardiovascular lin-eages: cardiomyocytes, vascular endothelial cells, and smooth muscle cells. Preclinical studies in small and large animals have thus far affirmed the beneficial effect of CPC transplantation on recipient myocardial function. 4 -6 More recently, phase I clinical trials have demonstrated improved left ventricular (LV) ejection fraction 7 or reduced scar mass and improved regional systolic wall thickening 8 at 4 -6 months after infusion of hCPCs for treatment of acute myocardial infarction.
Despite these promising initial results, little is known regarding important questions such as the optimal cell dose or delivery method, the rate of in vivo cellular survival, proliferation, engraftment and differentiation, or the mechanism(s) of potential therapeutic benefit in clinical hCPC trials. Translation of stem cell therapy has also been limited by poor engraftment and survival 9, 10 as well as unpredictable differentiation in vivo. 11, 12 In recent years, stem cell imaging has emerged as a valuable tool to quantitatively address some of these variables, and its implementation in clinical trials could add novel insight into the determinants of successful stem cell therapy. 13 Genetic engineering of stem cells is currently being explored as a means to image transplanted cells as well as overcome the aforementioned challenges. Stable ex vivo gene transfer into stem cells before their transplantation can be used to enhance stem cell homing, 14 survival, 15 imaging, 16 and targeted ablation. 16, 17 However, genetic engineering is limited by many of the challenges facing the gene therapy field at large. In particular, several current gene therapy approaches rely on retrovirus, lentivirus, or transposon elements, which catalyze random transgene integration into many potential sites. Randomly integrating vectors are not safe for clinical use because insertional mutagenesis can cause oncogenic activation and malignant transformation of cells. 18 Safe techniques for site-specific integration of transgenes into the human genome are therefore needed to overcome these shortcomings.
The phiC31 integrase is a site-specific recombinase that can be used to integrate transgenes into specific loci of the human genome. Specifically, the phiC31 integrase catalyzes recombination between attB and attP attachment sites, which are DNA recognition sequences of substantial size (Ϸ17bp). This enzyme can therefore be used to integrate a transgenecontaining plasmid carrying an attB site into pseudo-attP sites in the human genome. These specific loci of the human genome are known to produce robust, long-term transgene expression without risking proto-oncogene activation. 19 In the present study, we used this site-specific integration system to safely derive hCPC clones capable of long-term in vivo monitoring by using positron emission tomography (PET) or bioluminescence imaging (BLI). The resulting hCPCs are safe for use in humans because of their precisely known genetic makeup. Importantly, in addition to reporter gene imaging, this technique can be used to introduce a variety of genetic constructs safely and efficiently for enhanced cardiac stem cell therapy.
Methods

Isolation, Culture, and Characterization of Human Cardiac Progenitor Cells
Human CPCs were isolated based on a previously described protocol using magnetic separation in conjunction with a Sca-1 antibody. 20 -22 The study protocol was approved by the Stanford Institutional Review Board. In brief, human fetal hearts (StemExpress, Diamond Springs, CA) were perfused using a Langendorff apparatus, using Tyrode solution containing collagenase and protease. hCPCs were isolated by magnetic cell sorting (MACS, Miltenyl Biotec, Sunnyvale, CA), using Sca-1-coupled magnetic beads, according to the manufacturer's protocol. Sca-1 ϩ cells were eluted from the column by washing with PBS supplemented with 2% FBS and cultured on 0.1% gelatin-coated dishes in M199 (Gibco)/EGM-2 (3:1) supplemented with 10% FCS (Gibco), 10 ng/mL basic fibroblast growth factor (bFGF), 5 ng/mL epithelial growth factor (EGF), 5 ng/mL insulin-like growth factor (IGF-1), and 5 ng/mL hepatocyte growth factor (HGF). For isolation of human endothelial cells (hECs), please see the Online Data Supplement Methods for details. All hCPCs (unmodified and genetically modified) used for in vitro experiments and intramyocardial injection were at passage 10 to 16.
Flow Cytometry Analysis
Please see Online Data Supplement Methods for details.
Plasmid Constructs and Generation of Site-Specific Integrated Cell Lines
The donor construct pDB-FRT was generated by replacing the cassette coding GFP in a donor vector pDB2 23 containing an attB site with a triple fusion gene. 24 The plasmid pCSI expressing phiC31 integrase has been described. 25 To construct the donor plasmid pDB-FRT, a triple fusion gene coding firefly luciferase (Fluc), monomeric red fluorescent protein (mRfp), and herpes simplex virus truncated thymidine kinase (HSVttk) was cloned downstream of the CMV promoter. The hCPCs and hECs were grown and transfected with Fugene6, according to the manufacturer's instructions, using 3 L of reagent per 1 g of DNA. Transfections yielding integrasederived clones used 10 ng of pDB-FRT and 5 g of pCSI. After 24 hours, cells were split 1:30 to three 10-cm plates. At 48 hours after transfection, cells were selected in medium containing 350 g/mL of G418 (Invitrogen). Selection was continued for 10 to 14 days, at which time colonies became visible. Individual colonies were picked with a pipette tip and transferred to individual wells of a 24-well plate. Surviving colonies were expanded for PCR analysis. To screen for site-specific integrations, a nest PCR method using primers targeting 11 most frequent integration sites was used as described previously. 19 Briefly, a set of 11 primers were used for the firstround PCR to amplify the integration genes from the genomic DNA extracted from individual clones. The clones with site-specific integration demonstrated the expected size second-round PCR product and were selected for further characterization and functional studies.
Effect of Reporter Gene Expression on hCPC Viability, Proliferation, and Differentiation
In Vitro [ 18 F]-FHBG Accumulation Assay
Microarray Hybridization and Data Analysis
Surgical Model of Mouse Myocardial Infarction and hCPC Delivery
In adult female SCID Beige mice (Charles River Laboratories, Wilmington, MA), myocardial infarction (MI) was induced by ligation of the left coronary artery under 1.5% to 2% inhaled isoflurane anesthesia and confirmed by myocardial blanching and ECG changes. Animals were randomized into experimental groups receiving phiC31-hCPCs (nϭ30) or unmodified hCPCs (nϭ15) and a control group receiving PBS (nϭ15). All experimental animals were injected with 1ϫ10 6 cells, using a 31-gauge Hamilton syringe immediately after MI. In all groups, the volume of injection was 20 L at 3 sites near the peri-infarct border zone. All surgical procedures and injections were performed by a blinded, experienced microsurgeon (Y.G.).
In Vivo Optical BLI of Cell Survival in Transplanted Animals
[ 18 F]-FHBG PET Imaging of Cell Survival in Transplanted Animals
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Analysis of LV Function With Echocardiography and MRI
Echocardiography was performed before (day Ϫ7) and after (day 2, week 1, week 2, week 3, and week 4) the LAD ligation. The Siemens-Acuson Sequoia C512 system equipped with a multifrequency (8 -14 MHz) 15L8 transducer was used by an experienced operator (P.K.N.) blinded to the group designation. Analysis of M-mode images was performed using Siemens built-in software. LV volume at end of diastolic diameter (EDD) and end-systolic diameter (ESD), and volume of blood at end of diastole (BED) were measured and used to calculate LV ejection fraction by the formula: LVFSϭ[EDDϪESD]/BED. MRI was performed on a Sigma 3.0-T Excite HD scanner (GE Healthcare Systems, Milwaukee, WI) with a Mayo Clinic T/R MRI coil (Mayo Clinic Medical Devices, Rochester, MI) in a subset of animals (nϭ5/group). Mice were anesthetized with 2% isoflurane with oxygen (1 L/min) and placed in the prone position for imaging. A small-animal ECG and respiratory gating system (Small Animal Instruments, Stony Brook, NY) was used to acquire images as previously described. 26
Delivery of hECs in a Hind Limb Ischemia Model
Laser Doppler Perfusion Imaging
Blood flow to the ischemic or normal (nonischemic) hind limb was assessed using a PeriScan PIM3 laser Doppler system (Perimed AB, Stockholm, Sweden) as described previously. 27 Each animal was prewarmed to a core temperature of 37°C, and hind limb blood flow was measured before and after surgery on day 0 and again on days 3, 7, and 14. Regions of interest of the ischemic or nonischemic hind limb were drawn in a standard fashion. The level of perfusion in the ischemic and normal hind limbs was quantified using the mean pixel value within the region of interest, and the relative changes in hind limb blood flow were expressed as the ratio of the left (ischemic) over right (normal) mean pixel value.
Histological Examination
Statistical Analysis
Statistics were calculated using SPSS 12.0 (SPSS Inc, Chicago, IL). Descriptive statistics included mean and standard deviation. Oneway ANOVA and 2-way repeated-measures ANOVA with post hoc testing were used. Differences were considered significant at probability values of Ͻ0.05. 
Results phiC31 Integrase Mediates Site-Specific Integration of the Triple Fusion Reporter Gene
A donor vector containing the triple fusion reporter gene was designed as shown in Figure 1A . The triple fusion reporter gene encodes firefly luciferase (Fluc), monomeric red fluorescent protein (mRFP), and HSVttk to enable multimodal imaging using bioluminescence, fluorescence, and PET, respectively. This vector was cotransfected with the integration vector containing the phiC31 integrase into 293 cells to validate the site-specific integration system. The transfected cells were cultured in neomycin for 3 weeks to select stably-integrated cell clones. Genomic DNA was isolated from these clones, and primers for 3 typical integration sites were used to screen for site-specific integration of the triple fusion reporter transgene (Online Data Supplement Figure I) .
As expected, only the cells transfected with phiC31 integrase showed an appropriately sized PCR product, indicating unique transgene insertion at the intended genomic site.
Isolation and Derivation of Genetically Modified hCPC
We first isolated Sca-1 ϩ hCPCs from human fetal hearts and clonally expanded them using a previously described protocol. 21 The purity of the isolated progenitor cells was confirmed by cell surface marker expression (Online Data Supplement Figure II) . Then, one 60-mm cell culture dish containing approximately 1ϫ10 6 hCPCs was cotransfected with the donor and integration plasmids as shown in Figure 1A . After 3 weeks of growth in selection media containing neomycin, an average of 57 colonies was obtained (see Online Data Supplement Methods). Control transfections of the donor plasmid only (without the integration plasmid) yielded only 1 to 2 neomycin-resistant colonies, suggesting that transient expression of the phiC31 integrase substantially improved the rate of site-specific recombination. We then screened the genomic DNA of hCPCs for integration using a set of 44 pairs of primers. 19 The genomic DNA of pooled neomycin-resistant hCPCs reliably demonstrated integration in 3 well-characterized integration sites on chromosomes 19, 21, and X (19q13, 21q21, and Xq22; Figure 1B ; also see Online Data Supplement Methods). We screened 20 arbitrarily selected clones with 8p22, 19q13, 21q21, and Xq22 primers. From these 20 clones, we obtained 2 clones with a single integration: clone 16 contained a single integration at the 19q13 site and clone 7 contained a single integration at the 21q21 site ( Figure 1C ). Of note, only single integration sites were found in the clones obtained using phiC31 integration, whereas clones derived in parallel using lentiviral vectors displayed multiple integration sites, as evaluated by Southern blotting (Online Data Supplement Figure III) . We then chose the hCPC clone with known integration at the 19q13 site ( Figure 1D ) for subsequent functional experiments (designated phiC31-hCPCs).
Site-Specific Integration of the Triple Fusion Reporter Gene Does Not Alter hCPC Phenotype and Enables Robust Transgene Expression
Expression of the reporter gene from the "safe harbor" locus on chromosome 19 did not affect the cellular phenotype of hCPCs. Namely, integration of the reporter gene using phiC31 caused no discernible adverse effects on cellular proliferation (Online Data Supplement Figure IV) , karyotype (Online Data Supplement Figure V ), or gene expression profile (Online Data Supplement Figure VI ). Of note, hCPC clones derived using lentivirus did display a relative deficit in cellular proliferation capacity at 72 and 96 hours compared with untransduced hCPCs (Online Data Supplement Figure IV ). Most importantly, derivation of hCPC clones using phiC31 did not appreciably affect the differentiation propensity of hCPCs. phiC31-hCPCs retained expression of the Mef2C and Nkx2.5 cardiac transcription factors, as well as their ability to differentiate into cardiomyocyte, smooth muscle, and endothelial cell lineages, as evidenced by expression of the ␣-actinin, smooth muscle actin (SMA), or CD31 markers, respectively (Figure 2A and Online Data Supplement Figure  VII) . The gene expression profile of phiC31-hCPCs, as assessed by transcriptome microarray, was no different than that of untransduced hCPCs ( Figure 2B ). Finally, expression of the triple fusion reporter gene (Fluc-mRFP-HSVttk) from the 19q13 site was stable and robust. Fluc activity correlated linearly with cell number (R 2 ϭ0.99), as shown in Figure 2C Figure 2D and Online Data Supplement Figure  VIII) . As expected, HSVttk activity was diminished in phiC31modified hCPCs containing a single integration copy of the reporter gene, compared with lentivirally modified hCPCs that contained multiple randomly integrated copies of the reporter gene (Online Data Supplement Figure III) .
Intramyocardial Transplantation of hCPCs Improves LV Contractility
We next tested the efficacy of hCPC transplantation in ameliorating the effects of MI in mice. Adult NOD SCID mice were subjected to left anterior descending (LAD) artery ligation followed by injection with 1ϫ10 6 phiC31-hCPCs (nϭ30), 1ϫ10 6 unmodified hCPCs (nϭ15), or PBS control (nϭ15). Myocardial LV function after hCPC transplantation was assessed by echocardiography ( Figure 3A ) and cardiac MRI (Online Data Supplement Figure X, A) over the 8-week study period. At week 2 after transplant, phiC31-hCPCtreated hearts demonstrated a statistically significant improvement in fractional shortening (24.9Ϯ1.3% versus 19.8Ϯ1.0%; Pϭ0.0017; Figure 3B ) and ejection fraction (54.3Ϯ1.8% versus 45.6Ϯ1.5%; Pϭ0.0008; Online Data Supplement Figure X, B) compared with PBS controls. However, no statistically significant differences in contractility were observed between the hCPC-treated and untreated PBS controls at week 8 after transplant. As expected, the phiC31-hCPC-treated group did not display statistically significant differences from the unmodified hCPC-treated group at any of the tested time points.
Molecular Imaging of hCPC Survival in Ischemic Myocardium
We then evaluated the temporal kinetics of hCPC engraftment using BLI and PET. We carried out serial acquisitions concurrently over the 8-week study period and observed loss of both BLI and PET signal intensities over time, reflecting death of the transplanted cells ( Figure 4A ). When normalized to BLI signal intensity at day 1, the percentage of cells that survived was 22.7Ϯ11.5% at day 7, 15.7Ϯ7.7% at day 14, 10.6Ϯ5.1% at day 28, and 0.8Ϯ0.4% at day 56 ( Figure 4B) . These results were confirmed using PET imaging ( Figure 4C and 4D) and are in agreement with the results of other groups showing death of the majority of transplanted stem cells within 4 to 6 weeks after intramyocardial delivery. 9,28 -30 To confirm the results of our PET and BLI data, we also measured cell engraftment using real-time quantitative polymerase chain reaction (RT-qPCR). To this end, we used human-specific primers against Alu sequences to quantify the number of human genomes present within murine hearts at 14 and 28 days after transplantation. Our results using RT-qPCR were concordant with data obtained using PET and BLI. Namely, at days 14 and 28 after transplantation, 12.12Ϯ3.33% and 6.36Ϯ2.35% of unmodified hCPCs had successfully engrafted into murine myocardium. Similarly, at days 14 and 28 after transplantation, 11.37Ϯ3.55% and 6.65Ϯ2.46% of phiC31-hCPCs had successfully engrafted (Online Data Supplement Figure XI) .
We generated hECs containing site-specific integration of the triple fusion reporter gene by cotransfection of donor and integration vectors ( Figure 1A) . The transfected cells were clonally expanded and screened for integration at known pseudo-attP sites. 19 One of 20 clones was shown to have a single integration at the 8p22 site and was expanded for further characterization, and functional experiments phiC31-hECs were identical to untransduced hECs in their phenotype, as assessed by their expression of the endothelial cell marker CD31 (Ͼ90%), LDL uptake, and ability to form tubules in vitro (Online Data Supplement Figure XII ).
Transplantation of hECs Improves Ischemic Limb Perfusion
To assess cellular engraftment over time, we used BLI to evaluate the temporal kinetics of hEC survival ( Figure 5A ). Normalized to day 1, the BLI signals were 37.6Ϯ5.5% at day 4, 17.7Ϯ3.5% at day 7, and 11.3Ϯ2.1% at day 14 ( Figure  5B ). These results suggest acute death of hECs during the first week but relatively stable engraftment thereafter. We subsequently carried out laser Doppler blood perfusion (LDBP) monitoring to examine whether hEC delivery im-proved ischemic hind limb perfusion ( Figure 5C ). The hind limb perfusion ratio (ischemic/control hind limb) was significantly improved in the hind limbs transplanted with hECs compared with PBS at day 7 (0.41Ϯ0.05 versus 0.32Ϯ0.04, PϽ0.005) and day 14 (0.54Ϯ0.07 versus 0.41Ϯ0.04; PϽ0.005) after transplantation ( Figure 5D ). The hind limb perfusion ratios of phiC31-hECs and the unmodified hECs were similar. These data show that phiC31-hECs, despite their genetic modification, can be safely transplanted in vivo and retain their therapeutic capability to restore perfusion.
Discussion
In recent years, stem cell therapy has emerged as a promising approach to promote tissue repair after myocardial infarction. Despite encouraging initial results, clinical translation of cellular therapy has been impeded by several challenges, including poor engraftment, 31 malignant transformation, 32 or acute death of the transplanted cells. 33 Innovative approaches to overcome these challenges have relied on genetic modification of the delivered stem cells to enable expression of transgenes. Stable expression of such transgenes can enable a variety of valuable enhancements to cellular therapy, includ- There was no significant difference between the phiC31-hCPC and unmodified hCPC groups. C, Representative sections of the peri-infarct zone in the area of intramyocardial hCPC or PBS injection demonstrates the presence of phiC31-hCPCs. phiC31-hCPCs stained positive for the RFP antibody in the recipient myocardium at day 14 after injection. D, Representative hematoxylin and eosin staining of the heart sections show myocardial wall thickness of gross hearts at week 2 and week 6 after injection. E, Myocardial wall thickness of the hCPC groups are significantly increased compared with PBS control group at week 2 after transplantation. There was no significant difference between the phiC31-hCPC and unmodified hCPC groups. All hCPCs (unmodified and phiC31-modified) were transplanted intramyocardially at passage 10 to 16.
ing enhanced vasculogenesis, 34 improved cell survival, 15, 35 cellular tracking using clinical imaging modalities, 36 and the availability of a "safety switch" to induce apoptosis in the event of cellular misbehavior. 17 However, commonly used gene therapy vectors such as lentivirus and retrovirus can produce random integrations that are subject to the unpredictable effects of insertional mutagenesis. Hence, site-specific integration techniques are needed to safely translate gene therapy into the clinical setting. In recent years, stem and progenitor cells have emerged as exciting new tools for ameliorating LV dysfunction after MI. hCPCs hold considerable potential in this regard, as they are a clonogenic, self-renewing population that is preprogrammed for differentiation into cells of all 3 cardiac lineages in vitro: myocytes, smooth muscle cells, and endothelial cells. Several parameters for hCPC identification are currently found in the literature, including isolation of c-kit ϩ cells, 3 cardiosphere-derived cells, 37 Sca-1 ϩ cells, 21 and Isl1 ϩ cells. 38 These various hCPC formulations have all demonstrated a degree of efficacy in animal studies, although evaluation of the degree of overlap between these various populations and their comparative efficacy is still needed. We used Sca-1 ϩ hCPCs in this study, as we and others have found that hCPCs isolated using the Sca-1 antibody consistently provide high yields of homogeneous cells with identical morphology, differentiation, and surface marker expression. 21, 39, 40 However, the human equivalent for murine Sca-1 has not yet been identified. Presumably, the Sca-1 antibody cross-reacts with a human protein to yield a homogeneous population, but further work is needed to elucidate the identity of this epitope.
In the present study, we used the phiC31 integrase to achieve site-specific integration of a triple fusion reporter gene into a known chromosomal context in hCPCs and hECs. This proof-of-principle study demonstrates the utility of the phiC31 integration technique in producing both progenitor cells (hCPCs) and differentiated cells (hECs) that have been genetically modified to stably express a transgene of interest. Moreover, the techniques described herein are easily applied in any context with just basic molecular biology expertise and plasmid manipulation tools. 41 Genomic modification of hCPCs did not appreciably alter the progenitor cell phenotype, as assessed by global transcriptome microarray analysis and immunohistochemical analysis of differentiating progenitor cells. Indeed, phiC31-modified hCPCs retained their ability to improve myocardial contractility by a statistically significant margin compared with controls when assessed 2 weeks after intramyocardial injection. Likewise, phiC31modified hECs maintained their ability to improve ischemic hind limb perfusion after genomic modification.
We have the found the phiC31 integrase technique a facile and efficient approach for generating site-specific integrants in progenitor and differentiated cells. Alternate site-specific integration techniques are significantly less efficient than phiC31-integrase mediated recombination because they often rely on successful activation of the mammalian cell homologous recombination machinery. One such technique in- volves the introduction of a double-strand break at the desired genomic location by a tandem pair of zinc-finger nucleases (ZFNs). 42 Although ZFNs allow targeting of a wider variety of genomic loci, their design and validation require extensive time and expertise. In addition to verifying proper targeting, cell exposure to ZFNs must be minimized in order to prevent any off-target cleavage events. The phiC31 integrase system is easily implemented using common plasmid manipulation and molecular biology techniques.
In summary, our report establishes for the first time the feasibility of site-specific genetic integration in human cardiac progenitor cells and human endothelial cells using nonviral vectors. This type of genetic engineering of human stem cells enables a multitude of improvements to overcome many of cellular therapy's current limitations. The ease, efficiency, and safety of the phiC31 integrase system make it an appealing approach to such attempts at stable genetic modification of therapeutic cell populations. Figure 5 . Improvement in hind limb perfusion after transplantation of human endothelial cells (hECs). A, Localization and survival of phiC31-human endothelial cells in the ischemic hind limb after intramuscular delivery as assessed by bioluminescence imaging (BLI). B, Quantification of BLI signal in the hind limb after cell delivery. C, Representative laser Doppler perfusion images of an adult female SCID Beige mouse injected with 1ϫ10 6 unmodified hECs or 1ϫ10 6 phiC31-hECs at 1, 3, 7, and 14 days after cell delivery showing improved blood flow for the treatment group relative to PBS controls. D, The mean hind limb perfusion ratio (ischemic/control hind limb) was significantly improved in hEC-treated mice compared with the PBS-treated mice (*PϽ0.05, transplant groups versus control groups at day 14 after transplant). There was no significant difference between the phiC31-hEC and unmodified hEC groups (nϭ5 per group).
